Increasing Access to Biosimilars Act of 2021

Summary

Increasing Access to Biosimilars Act of 2021 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 28 April 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

2. 28 April 2021

   Introduced

   Introduced in House

   Source: IntroReferral

3. 28 April 2021

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

4. 28 April 2021

   Introduced

   Introduced in House

   Source: IntroReferral

5. 29 April 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 28 April 2021 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 28 April 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 28 April 2021

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 28 April 2021

  Open at official source

Sponsors

• Tony Cárdenas · D · Sponsor
• Angie Craig · D · Sponsor
• Sen. Blunt Rochester, Lisa [D-DE] · D · Cosponsor
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to → Increasing Access to Biosimilars Act of 2021
• related to ← Increasing Access to Biosimilars Act of 2020